Reference
HPRA. LYNPARZA (Olaparib) - Important Safety Information from AstraZeneca Pharmaceuticals (Ireland) DAC as approved by the HPRA Internet Document : 27 Nov 2020. Available from: URL: https://www.hpra.ie/homepage/medicines/safety-notices/item?t=/lynparza-(olaparib)---important-safety-information-from-astrazeneca-pharmaceuticals-(ireland)-dac-as-approved-by-the-hpra&id=46720e26-9782-6eee-9b55-ff00008c97d0
Rights and permissions
About this article
Cite this article
HPRA advises of risk of medication errors with olaparib. Reactions Weekly 1834, 3 (2020). https://doi.org/10.1007/s40278-020-87195-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-020-87195-2